Cronos Closes Dutch Cannabis Deal, Claims European Market Lead

TORONTO – Cronos Group Inc. completed the acquisition  of CanAdelaar B.V., securing the undisputed market-share leader inside the Dutch Wietexperiment – a government-designed, closed-loop Cannabis supply pilot. The base purchase price stands at €57.5 million (approx. US$67 million), with performance-linked cash payments tied to CanAdelaar’s EBITDA in both 2026 and 2027.

CanAdelaar is the only large-scale greenhouse cultivator among the ten licensed producers supplying Cannabis to the Wietexperiment’s 69 participating coffee shops, spread across ten Dutch municipalities. The regulatory framework requires those shops to source exclusively from licensed producers. No imports. No inter-producer sales.

The company’s Voorne aan Zee facility spans 540,000 sq. feet and yields roughly 20,000 kilograms of dried flower annually, enough to supply nearly every shop in the program under its C.O.G. (CanAdelaar Original Grow) brand. Revenue scaled from €15.2 million in 2024 to €40.6 million for the twelve months ended September 30, 2025, with adjusted EBITDA reaching €24.2 million across the same period.

Cronos is paying a premium for that position. The base purchase price values CanAdelaar at roughly 1.4x annualized net revenue and 2.9x adjusted EBITDA based on first-half 2026 results – multiples that reflect competitive standing as much as cash flow.

“This is a milestone for Cronos,” said Chairman, President and CEO Mike Gorenstein. “We have established a meaningful and scalable platform in Europe’s largest adult-use cannabis market.” Christopher Martens, CanAdelaar’s former CEO, transitions to General Manager, Cronos Netherlands – a continuity structure designed to keep operations stable through integration.

Cronos frames the deal around what it calls a borderless product strategy, transplanting its genetic breeding, R&D investments, and brand portfolio into regulated markets as they open. With flower accounting for more than 60% of CanAdelaar’s current revenue, the company sees clear room to push into derivative categories already permitted under the program, including edibles, vapes, pre-rolls, and hash.

The Wietexperiment currently serves roughly 1.7 million Dutch residents out of a national population of 18.1 million. Amsterdam and the vast majority of the country’s 562 coffee shops still operate outside the regulated supply chain. A Dutch government interim report published in September 2026 described early experiences as predominantly positive, though no formal timeline for broader expansion has been announced.

Cronos committed capital to the Wietexperiment before its outcome is fully established. That is a calculated risk, but a structurally sound one. The program’s compliance architecture, government oversight, and closed supply chain are precisely the conditions that publicly traded Cannabis operators have needed to justify European allocation. If the Netherlands eventually extends regulated supply to the roughly 500 coffee shops still operating outside the system, Cronos’ position inside the program’s dominant producer could represent the most cost-efficient European entry point the sector has produced to date.